Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery

Phase 1

Active, not recruiting

• Conditions: Deep Venous Thrombosis
• Interventions: Drug: Low Molecular Weight Heparine; Drug: Direct Oral Anticoagulant.

• Registration Number: NCT06913595
• Lead Sponsor: Cairo University

Brief Summary

Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant

Detailed Description

This study aims to compare the effectiveness of rivaroxaban versus low molecular weight heparin in reducing the incidence of PMVT after bariatric surgery.

Study Timeline

• Study Start: 2024-03-25
• Study First Submitted: 2025-03-24
• Status Verified: 2025-04
• Study First Submitted QC: 2025-04-03
• Last Update Submitted: 2025-04-03
• Study First Posted: 2025-04-06
• Last Update Posted: 2025-04-06
• Primary Completion: 2025-05-25
• Study Completion: 2025-06-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• BARIATRIC PATIENTS

Exclusion Criteria

• BLEEDING TENDENCY

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Low Molecular Weight Heparin	Low Molecular Weight Heparine	Low molecular weight heparin as aprophylaxis after bariatric surgery
Direct Oral Anticoagulant.	Direct Oral Anticoagulant.	Direct Oral Anticoagulant as aprophylaxis after bariatric surgery

Primary Outcome Measures

Name	Time	Method
VENOUS THROMBOEMBOLISM	1 year	DVT after bariatric surgery

Trial Locations

Locations (1)

Cairo University; 🇪🇬 Cairo, Egypt